Novo Nordisk: acquisition of Cardior Pharmaceuticals
Cardior Pharmaceuticals is a leader in the discovery and development of RNA-targeted therapies to prevent, repair and reverse heart disease.
The agreement includes Cardior's lead compound 'CDR132L', currently in phase 2 clinical development for the treatment of heart failure.
This acquisition is an important step in Novo Nordisk's strategy to establish a presence in the field of cardiovascular disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction